{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Zura Bio Limited"},"Symbol":{"label":"Symbol","value":"ZURA"},"Address":{"label":"Address","value":"Cayman Islands"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Caribbean"},"CompanyDescription":{"label":"Company Description","value":"Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California."},"CompanyUrl":{"label":"Company Url","value":"https://www.zurabio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Gary Whale","title":"Chief Technology Officer"},{"name":"Kiran Nistala","title":"Chief Medical Officer & Head-Development"},{"name":"Robert Lisicki","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}